Page 14 - BB Neuromedicine Highlights 2019

of 31 percent. Neuronetics also
recently went public in June with
an IPO of $93.5 million.
magneTiC Therapy For
depreSSion — neuronet-
iCs CarToon
Two out of every three people
treated with magnetic therapy for
depression have a good response
even after a year.
After eight rounds of venture
capital funding, and backers like
GE and Pfizer, Neuronetics was
recognized as the real deal. Its
magnetic therapy for depression
system accounts for the bulk of
the company’s success.
For individuals with depression,
treatment is quite safe. In fact, it antidepressants over time. strong evidence for its effective- Neuronetics offers a great option
has much fewer side effects when Notably, healthcare provid- ness is readily apparent. of care. Magnetic therapy for
compared to antidepressants. ers are realizing the benefits of depression is recommended as a
It also has no impact on magnetic therapy for depres- neuroneticS – a Leader treatment of choice after initial
individuals’ ability to think or sion. Neuronetics has installed oF innovaTion in mediCal antidepressants fail to show a re-
concentrate. This, as well as its over 900 units in the U.S. alone. deviCes sponse. As more patients realize
level of effectiveness, are reasons Neuronetics is also entering into Neuronetics recently an- its effectiveness and lower risk of
Neuronetics’ system is attracting the Japanese healthcare market nounced its 2018 revenue side effects, it may ultimately be
so much attention. this coming year. With over two earnings. In total, the company a first line treatment. Evidence
million magnetic therapy for generated $52.8 million over the so far certainly suggests this will
magneTiC Therapy For depression sessions completed, past year representing a growth likely be the case.
depression versus anTi-
depressanTs
When it comes to antidepres-
sants, the numbers aren’t good.
For those initially placed on an
antidepressant for depression,
slightly more than a quarter have
an effective response long-term.
The response rates are even less
after the second or third trials of
the drugs.
In contrast, two out of every
three people treated with mag-
netic therapy for depression have
a good response even after a
year. Nearly half enjoy remission
of their symptoms completely.
Though monthly maintenance
treatments may be needed, Neu-
ronetics’ system appears both
safer and more effective than